Table 1.
Baseline Characteristics and Continuation of Dual Antiplatelet Therapy
| Variable | Total, N = 2110a | Thienopyridine, n = 554 | No Thienopyridine, n = 1545 | P Value |
|---|---|---|---|---|
| Demographics | ||||
| Age ≥75 years | 283 (13) | 76 (14) | 204 (13) | 0.76 |
| Male sex | 1581 (75) | 407 (73) | 1168 (76) | 0.32 |
| White race | 2005 (95) | 522 (95) | 1473 (96) | 0.35 |
| Region | ||||
| North America | 700 (33) | 353 (64) | 347 (22) | <0.001 |
| South America | 101 (5) | 16 (3) | 83 (5) | |
| Western Europe | 598 (28) | 64 (12) | 526 (34) | |
| Eastern Europe | 386 (18) | 74 (13) | 311 (20) | |
| Rest of world | 325 (15) | 47 (9) | 278 (18) | |
| Risk factors | ||||
| DM | 453 (21) | 120 (22) | 330 (21) | 0.88 |
| Current smoker | 782 (37) | 183 (33) | 596 (39) | 0.021 |
| Hypertension | 1316 (62) | 363 (66) | 947 (61) | 0.078 |
| Hypercholesterolemia | 1295 (61) | 373 (67) | 915 (59) | <0.001 |
| Previous MI | 363 (17) | 111 (20) | 249 (16) | 0.036 |
| Previous CHF | 65 (3) | 16 (3) | 49 (3) | 0.74 |
| CrCl <60 mL/min | 215 (10) | 54 (10) | 160 (10) | 0.68 |
| TRITON‐TIMI 38 presentation and treatment | ||||
| Qualifying NSTE‐ACS | 1608 (76) | 488 (88) | 1110 (72) | <0.001 |
| CABG | 2 (0.09) | 0 (0) | 2 (0.13) | 0.40 |
| BMS only | 966 (46) | 128 (23) | 830 (54) | <0.001 |
| DES only | 1045 (50) | 397 (72) | 645 (42) | <0.001 |
| DES (any) | 1144 (54) | 426 (77) | 715 (46) | <0.001 |
| ACEI/ARB | 1501 (71) | 383 (69) | 1111 (72) | 0.22 |
| β‐Blocker | 1891 (90) | 496 (90) | 1385 (90) | 0.94 |
| Statin | 1934 (92) | 519 (94) | 1405 (91) | 0.045 |
| Randomization group (prasugrel) | 1070 (51) | 278 (50) | 785 (51) | 0.80 |
| Events and follow‐up in TRITON‐TIMI 38 | ||||
| TIMI major non‐CABG bleed | 28 (1.3) | 10 (1.8) | 18 (1.2) | 0.26 |
| TIMI major/minor non‐CABG bleed | 52 (2.5) | 15 (2.7) | 37 (2.4) | 0.69 |
Abbreviations: ACEI, angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARC, Academic Research Consortium; BMS, bare‐metal stent; CABG, coronary artery bypass grafting; CHF, congestive heart failure; CrCl, creatinine clearance; DES, drug‐eluting stent; DM, diabetes mellitus; MI, myocardial infarction; NSTE‐ACS, non–ST‐segment elevation acute coronary syndrome; TIMI, Thrombolysis In Myocardial Infarction; TRITON‐TIMI 38, Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis In Myocardial Infarction 38.
Data are presented as n (%).
a
Thienopyridine status missing in 11 patients.